A clear, data‑driven view of the commercial state of biopharma and medtech
The global pharmaceutical industry entered 2025 facing continued uncertainty, but deal‑making told a more nuanced story.
In our 2025 Deal‑making Roundup, we analyzed the alliances, M&A, and financing activity that defined the commercial landscape across biopharma, medtech, and diagnostics. Drawing on comprehensive Biomedtracker data, the report shows where capital flowed, which therapeutic areas commanded premium valuations, and how deal structures evolved as companies recalibrated risk and reward.
What you’ll learn:
- How 2025 deal‑making signaled a shift toward fewer, higher‑value partnerships and acquisitions across biopharma and medtech.
- Which therapeutic areas captured the greatest share of alliance activity, capital, and strategic attention.
- How evolving deal structures, including milestone‑heavy agreements, reflect changing risk‑sharing and valuation models.
- What alliance, M&A, and financing trends reveal about the overall health and direction of the pharma commercial market.
